louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03255551: Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure
Official title: Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients With Hypertension: Prospective, Multicenter, Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2017-08-21
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Estimated total number of patients: 3,150 Estimated number of centers: 37

Brief summary: Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients with Hypertension

Detailed description: After taking Amozatan (AMS, amlodipine / rozanthin combination) in patients with essential hypertension, the percentage of patients who reached the mean systolic target blood pressure was evaluated

Eligibility criteria: Inclusion Criteria:

* Patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or rosartan monotherapy
* In patients with stage 2 hypertension (SBP 160-179 mmHg), patients requiring a combination therapy to reach the target blood pressure
* Patients who were changed to amosartan while using other hypertensive agents

Exclusion Criteria:

* Patients with hypersensitivity to dihydropyridine derivatives of amosartan
* Women who are pregnant or who may be pregnant and breastfeeding
* Patients with severe hepatic dysfunction
* Patients with severe aortic stenosis
* Patients at risk of shock
* Patients participating in other clinical studies

Primary outcomes:
measure: Patients with essential hypertension evaluated the mean blood pressure after taking amosartan.
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Kim SH, Ryu KH, Lee NH, Kang JH, Kim WS, Park SW, Lee HY, Kim JJ, Ahn YK, Suh SY. Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study. BMC Res Notes. 2011 Oct 28;4:461. doi: 10.1186/1756-0500-4-461.
citation: Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003 Jun 28;326(7404):1427. doi: 10.1136/bmj.326.7404.1427.
citation: Choi SM, Seo MJ, Kang KK, Kim JH, Ahn BO, Yoo M. Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats. Arch Pharm Res. 2009 Mar;32(3):353-8. doi: 10.1007/s12272-009-1307-x. Epub 2009 Apr 23.
Clinical trial NCT00825851: Effect of Smoking, Abstention and Nicotine Replacement Therapy on Wound Healing
Official title: Effect of Smoking, Abstention and Nicotine Replacement Therapy on Wound Healing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Wound Healing
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
Collaborators: name: The Danish Medical Research Council
First posted: 2009-01-21
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The aim was to determine the wound healing capacity in healthy never smokers and smokers who continue to smoke, or quit smoking using transdermal nicotine patch versus placebo patch.

Detailed description: Two wound healing models were applied: the excisional skin biopsy model to study wound histology and the suction blister model to study epidermal regeneration and skin transudate. In addition blood sampling was made to validate compliance to the study arms and to study systemic markers of collagen metabolism and oxidative stress. In addition, wound infections and wound ruptures were recorded post hoc as complications to the excisional skin biopsy model were not expected to occur.

Eligibility criteria: Inclusion Criteria:

* daily smokers smoking between 15-25 cigarettes per day and never smokers

Exclusion Criteria:

* chronic medical disease
* atopic dermatitis or other skin disease
* pregnancy
* menopause
* allergy to dressings or patches
* current or recent medication with corticosteroids or NSAID

Primary outcomes:
measure: wound healing
timeFrame: 1, 4, 8, and 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Bispebjerg Hospital
Study officials:
affiliation: Bispebjerg Hospital
name: Lars T Sorensen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sorensen LT, Karlsmark T, Gottrup F. Abstinence from smoking reduces incisional wound infection: a randomized controlled trial. Ann Surg. 2003 Jul;238(1):1-5. doi: 10.1097/01.SLA.0000074980.39700.31.
Clinical trial NCT00998751: Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
Official title: Phase 2 Study of Oral AB1010 in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Gastro-intestinal Stromal Tumours
Keywords: cKIT inhibitor
GIST
Lead sponsor: AB Science
Sponsor class: INDUSTRY
First posted: 2009-10-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.


Eligibility criteria: Inclusion Criteria:

* Male or Female patients, age \>18
* Life expectancy \> 6 months
* Histological proven, metastatic, or locally advanced and non-operable, non- pre-treated GIST.
* Patients having never received any tyrosine kinase inhibitor, including as adjuvant therapy
* C-Kit (CD117) positive tumors detected immuno-histochemically
* Measurable tumor lesions with longest diameter \>20 mm using conventional techniques or \>10 mm with spiral CT scan

Exclusion Criteria:

* Documented allergy to the similar drug of AB1010
* Inadequate organ function
* Patients with a history of any other malignancy

Primary outcomes:
measure: Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST)
timeFrame: 2 months
Secondary outcomes:
measure: Progression Free Survival
timeFrame: until disease progression
Other outcomes:
Locations:
city: Villejuif
country: France
facility: Lecesne
Study officials:
References:
citation: Le Cesne A, Blay JY, Bui BN, Bouche O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer. 2010 May;46(8):1344-51. doi: 10.1016/j.ejca.2010.02.014. Epub 2010 Mar 6.
Clinical trial NCT05221151: Melatonin vs Pregabalin for Anxiolysis and Sedation
Official title: Efficacy of Preoperative Melatonin Versus Pregabalin on Intraoperative Anxiolysis and Sedation During Hip Arthroplasty Under Regional Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Anxiety
Keywords: melatonin
pregabalin
Lead sponsor: Menoufia University
Sponsor class: OTHER
First posted: 2022-02-02
Enrollment: 78
Sex: ALL
Minimum age (years): 55
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: preoperative melatonin, pregabalin or both will be given to all patients preoperative

Detailed description: On arrival at the operating room, continuous electrocardiogram, non-invasive blood pressure and pulse oximetry monitors will be applied. Sedation score (ramsay sedation score)(10) will be recorded on arrival to OR An 18-gauge cannula will be inserted in a peripheral vein and a warmed (37°C) lactated Ringer solution infusion was started. Ondansetron 4 mg will be administered intravenously as a prophylaxis against nausea and vomiting. Thereafter the patient will be supported in the sitting position. Intrathecal anaesthetic (room temperature hyperbaric bupivacaine 0.5% (20 mg) + fentanyl 25 μg (0.5 mL) will be given under complete aseptic technique . The patient was returned to the supine position for 15 min then to lateral position with operative side up.

HR and blood pressure will be measured every 2.5 minutes intraoperatively, however, the values will be recorded in the anesthesia chart only every five minutes for 2 hours then every 15 minutes for 3 hours. Durations will be calculated considering the time of spinal injection as time zero.

Hypotension (SAP\<100 mmHg or \<80% of the baseline measured before spinal anaesthesia) will be treated by ephedrine 6 mg, to be repeated if inadequate response within 2 minutes. If bradycardia (HR≤60 bpm) developed, atropine (0.6 mg) will be given to restore adequate HR (≥60 bpm).

Eligibility criteria: Inclusion Criteria:

* ASA I or II
* patients undergoing hip arthroplasty
* patient consent for spinal anaesthesia
* patient alert, concious and good mental condition

Exclusion Criteria:

* Patients with any neurolgical or psychiatric history before the procedure
* Patients with a history of chronic pain
* patients with known allergy to any of this study drugs
* patients have Any contraindication to neuraxial block.

Primary outcomes:
measure: VAS
timeFrame: on arrival to operating room then every 6 hours untill 48 hours
measure: Ramsey Sedation scale
timeFrame: on arrival to operating room then every 6 hours untill 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: Faculty of Medicine, University Hospitals
state: Menoufia
Study officials:
References:
Clinical trial NCT02912351: A Post-Market Retrospective Study on Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis
Official title: A Post-Market, Single-Center, Retrospective Study to Collect Clinical Outcomes and Safety Data From Patients Who Have Undergone Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis and Are at Least 2 Years Past Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoarthritis
Keywords: Total Knee Arthroplasty
Total Knee Replacement
Revision Knee Arthroplasty
Lead sponsor: Medacta USA
Sponsor class: INDUSTRY
First posted: 2016-09-23
Enrollment: 24
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: For patients that had received the treatment modality, GMK Revision Knee System and are at least 2 years (24 months) out from surgery.

Brief summary: This is a retrospective, single-site observational study, designed to assess the clinical outcomes and collect safety data of GMK Revision knee system used for primary or revision total knee arthroplasty at minimum two years post-treatment.


Eligibility criteria: Inclusion Criteria:

* Patients who are willing and able to provide written informed consent for participation in the study. Written informed consent must be obtained prior to any study procedure.
* Patients with ability to understand and provide written authorization for use and disclosure of personal health information
* Patients must be willing to comply with the post-operative evaluation schedule.
* Patients underwent either a primary or revision total knee replacement for any type of etiology (Osteoarthritis, Avascular necrosis, Rheumatoid Arthritis, Post-traumatic Arthritis, Polyarthritis, Primary implantation failure).
* Patients must have received a GMK Revision component
* Patients must be at minimum 2 year (24 months) post-treatment
* The operation was performed or supervised by the investigator.
* No age limit criteria

Exclusion Criteria:

* History of alcoholism
* Currently on chemotherapy or radiation therapy
* Habitual use of narcotic pain medications prior to surgery or after surgery for reasons other than knee pain
* History of a metabolic disorder affecting the skeletal system other than osteoarthritis or osteoporosis
* History of chronic pain issues for reasons other than knee pain
* Women that are pregnant

Primary outcomes:
measure: Total Knee Society Scores (KSS)
timeFrame: Minimum 2 years post surgery
Secondary outcomes:
measure: Radiographic Analysis
timeFrame: Minimum 2 years post surgery
measure: Patient Satisfaction
timeFrame: Minimum 2 years post surgery
measure: Complication Assessment
timeFrame: minimum 2 years post surgery
Other outcomes:
Locations:
city: Boise
country: United States
facility: Saint Alphonsus Medical Group
state: Idaho
Study officials:
affiliation: Medacta USA, Inc.
name: Mukesh Ahuja, MBBS, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT00567151: Co-Infection of NTM in Patients With Smear Positive Pulmonary TB
Official title: Detection of Nontuberculous Mycobacterial co-Infection Using Duplex PCR for Mycobacterial Hsp 65 Gene and Its Clinical Significance in Patients With Smear Positive Pulmonary Tuberculosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis, Pulmonary
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2007-12-04
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients visited Seoul National University Hospital

Brief summary: The aim of this study is to elucidate the prevalence of nontuberculous mycobacterial (NTM) co-infection in patients with smear positive pulmonary TB. To detect the NTM co-infection, we will perform duplex PCR targeted for mycobacterial hsp 65 gene using sputa. In addition, the clinical significance of this co-infection will be evaluated.


Eligibility criteria: Inclusion Criteria:

* New patients with pulmonary TB
* Sputum AFB smear-positivity

Exclusion Criteria:

* Non-applicable

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National Univeristy Hospital
name: Jae-Joon Yim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05615051: Influence of Implant Surface Decontamination on the Reconstructive Outcomes of Peri-implantitis
Official title: Influence of Implant Surface Decontamination on the Reconstructive Outcomes of Peri-implantitis: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Peri-Implantitis
Lead sponsor: Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain
Sponsor class: OTHER
First posted: 2022-11-14
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized clinical trial
Primary purpose: TREATMENT

Brief summary: Two groups are aimed at being investigated in three centers (CICOM, Clinica Branemark and Clinica Joan Pi)

* Test group: Group electrolytic approach (EA): Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) during 2 minutes
* Control group: Group hydrogen peroxide (HP): Mechanical detoxification using curettes + NiTi brushes + hydrogen peroxide 5% for 2 minutes soaked in a gauze Patients´ group selection will be randomly allocated. For patients whom their personal clinical record # ends in a number from 0 to 4 will be included in the test group, while for patients whom their personal clinical record # ends from 5-9 will be included in the control group.

The infra-osseous component will be regenerated using xenograft (Creos, NB) + autogenous bone in a ratio 1:1 harvested from the adjacent area. A resorbable membrane (Creos, NB) will be placed to compartmentalize the infra-osseous component following a poncho-like approach.


Eligibility criteria: Inclusion:

* Screw-retained or cement-retained fixed or removable implant-supported prosthesis for a minimum of 36 months.
* All patients in age of 18 to 80
* non-smokers
* no presence of systemic disease or medication known to alter bone metabolism
* partial or complete edentulous patients that have no active periodontal disease.

Exclusion criteria:

* pregnancy or lactation
* history of or current smokers
* uncontrolled medical conditions,
* lacking keratinized mucosa (≤2mm) on the lingual or buccal implant sites,
* advanced(A) peri-implantitis (\>50% of the implant length).

Primary outcomes:
measure: Resolution of the disease
timeFrame: 12 months
Secondary outcomes:
measure: Radiographic bone gain and clinical outcomes
timeFrame: 12 months
Other outcomes:
Locations:
city: Badajoz
country: Spain
facility: Clinica CICOM
Study officials:
References:
Clinical trial NCT04017351: Virtual Assistant for Plastic Surgery Patients
Official title: Virtual Assistant for Plastic Surgery Patients - Impact on the Clerical Burden, Resource Utilization, Patient and Provider Satisfaction, and Patient Surgical Outcomes.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Surgery
Keywords: Plastic
Virtual Assistant
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2019-07-12
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Researchers are trying determine the long term impact when patients have access to the artificial intelligence virtual assistant (AIVA) as a complimentary resource.

Detailed description: Eligible subjects will be randomized into to two groups. One group of subjects will be given access to the AIVA will be instructed to ask, at home, questions regarding the planned surgery to the AIVA application on their mobile phone. The other group will be instructed to call to the Standard of Care call center with questions related to their treatments. Researchers will follow up with all subjects from both groups for a 1 year amount of time.

Eligibility criteria: Inclusion Criteria:

* Subjects above 18 years old
* Able to use applications on mobile phones and consent to participate
* Adult subjects in the Plastic Surgery outpatient clinic of Mayo Clinic Florida

Exclusion Criteria:

-

Primary outcomes:
measure: Number of phone calls
timeFrame: 12 months
measure: Duration of phone call
timeFrame: 12 months
measure: Nature of phone call
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Antonio Forte, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02969551: Detection of Airway Obstruction by Manometry in Different Sleep Stages and Comparing it to DISE
Official title: Detection of Airway Obstruction by Manometry in Different Sleep Stages and Comparing it to DISE
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sleep Apnea Syndromes
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2016-11-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with a diagnosed obstructive sleep apnea Syndrome.

Brief summary: Patients with OSA receive manometry measurements with Apneagraph (AG) during one night of sleep. All patients are simultaneously evaluated with polysomnography. Patients who are not eligible for CPAP therapy are additionally studied with drug-induced sleep endoscopy (DISE). The frequency and obstructions patterns in different sleep stages are assessed. In addition obstruction patterns detected with AG are compared with DISE examination in the selected cases.


Eligibility criteria: Inclusion Criteria:

* Apnea-Hypopnea-Index (AHI) ≥ 5.

Exclusion Criteria:

* age \<18 years;
* body mass index (BMI) of \>35 kg/m2; active infection;
* previous oral, head, or neck surgery in the last 3 months; pregnancy; chronic use of alcohol (\> 60g ethanol per day or \> 150g ethanol per week) or sedatives; illicit drug use;
* chronic obstructive pulmonary disease.

Primary outcomes:
measure: Detection of obstruction depending of sleep stage
timeFrame: 8
Secondary outcomes:
measure: Comparing the manometry findings to DISE
timeFrame: 1 Hour
Other outcomes:
Locations:
city: München
country: Germany
facility: Klinik für Hals- Nasen- Ohrenheilkunde
state: Bayern
Study officials:
affiliation: attending doctor in ENT
name: Clemens Heiser, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04708951: Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®
Official title: A Prospective Randomized Comparison of Colonoscopy Adenoma Detection Rate With a Disposable Cap (ENDOCUFF VISION®) (Endocuff) Versus a Permanently Mounted Balloon (G-EYE®)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adenoma
Colorectal Cancer
Keywords: Adenoma
Colorectal Cancer
Lead sponsor: Dr. Horst Schmidt Klinik GmbH
Sponsor class: INDUSTRY
First posted: 2021-01-14
Enrollment: 970
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Subjects will be randomized to one of two groups - ECV colonoscopy or G-EYE® colonoscopy
Primary purpose: SCREENING

Brief summary: The study is intended to compare the detection rate obtained by performing G-EYE® high definition colonoscopy vs. the detection rate obtained by performing ECV high definition colonoscopy.

Detailed description: This is a multicenter, two-arm, randomized, open-label study intended to compare the detection rate obtained by performing G-EYE® high definition colonoscopy vs. the detection rate obtained by performing ECV high definition colonoscopy.

Eligibility criteria: Inclusion Criteria:

1. Screening and surveillance population for Adenoma and CRC.
2. The patient must understand and sign a written informed consent for the procedure.

Exclusion Criteria:

1. Subjects with inflammatory bowel disease;
2. Subjects with a personal history of hereditary polyposis syndrome;
3. Subjects with suspected chronic stricture potentially precluding complete colonoscopy;
4. Subjects with diverticulitis or toxic megacolon;
5. Subjects with prior colonic surgery (exclusion appendectomy)
6. Subjects with a history of radiation therapy to abdomen or pelvis;
7. Pregnant or lactating female subjects;
8. Subjects who are currently enrolled in another clinical investigation.
9. Subjects with current oral or parenteral use of anticoagulants, not considered eligible by the investigator.
10. Subjects with recent (within the last 3 mounts) coronary ischemia or CVA (stroke)
11. Any patient condition deemed too risky for the study by the investigator

Primary outcomes:
measure: Comparison between adenoma detection rate of G-EYE® colonoscopy and EndoCuff Vision®
timeFrame: June 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: IU Health University Hospital
state: Indiana
city: New York
country: United States
facility: NYU Langone Health
state: New York
city: Wiesbaden
country: Germany
facility: Helios Dr. Horst Schmidt Kliniken Wiesbaden
Study officials:
affiliation: Helios Dr. Horst Schmidt Kliniken Wiesbaden
name: Ralf Kiesslich, Prof.
role: PRINCIPAL_INVESTIGATOR
References: